Mainstream

Rhythm Pharma gains as mid-stage trial for rare form of obesity succeeds

Rhythm Pharma gains as mid-stage trial for rare form of obesity succeeds

Post ContentrytmRead More

You might also be interested in reading MakerDAO Risk Core Unit makes urgent parameter change request in light of recent market events.

July 9, 2025
In Mainstream